Loading
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
Latest quote
$20.13
−$0.16 · -0.79%
After-hours
$20.13
$0.00 · 0.00%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
Day range
Current $20.13
52-week range
Current $20.13
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
29
Expensive
Sentiment
74
Bullish
Risk
56
Elevated Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
Day range
Current $20.13
52-week range
Current $20.13
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 18.15M USD | 12.92M USD | 15.38M USD | 13.23M USD | 9.55M USD |
| Selling, general, and administrative | 9.42M USD | 6.93M USD | 7.52M USD | 6.01M USD | 3.35M USD |
| Operating expenses | 27.57M USD | 19.85M USD | 22.9M USD | 19.23M USD | 12.89M USD |
| Interest income | 1.13M USD | 847K USD | 637K USD | 149K USD | 4K USD |
| Operating income | −27.57M USD | −19.85M USD | −22.9M USD | −19.23M USD | −12.89M USD |
| Net income | −26.44M USD | −19M USD | −22.26M USD | −19.09M USD | −12.89M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$37.33
85.44% upsideAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
